{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:57:39Z","timestamp":1715993859977},"reference-count":54,"publisher":"Hindawi Limited","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1095,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Ther"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1111\/j.1529-8019.2012.01486.x","type":"journal-article","created":{"date-parts":[[2012,10,9]],"date-time":"2012-10-09T13:03:42Z","timestamp":1349787822000},"page":"443-451","source":"Crossref","is-referenced-by-count":9,"title":["Alternatives for the treatment of local advanced disease: electrochemotherapy, limb perfusion, limb infusion, intralesional IL2. What is the role?"],"prefix":"10.1155","volume":"25","author":[{"given":"Alessandro","family":"Testori","sequence":"first","affiliation":[{"name":"Melanoma and Sarcoma Surgery; European Institute of Oncology; Milan; Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Intelisano","sequence":"additional","affiliation":[{"name":"Melanoma and Sarcoma Surgery; European Institute of Oncology; Milan; Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Verrecchia","sequence":"additional","affiliation":[{"name":"Melanoma and Sarcoma Surgery; European Institute of Oncology; Milan; Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Menicanti","sequence":"additional","affiliation":[{"name":"Melanoma and Sarcoma Surgery; European Institute of Oncology; Milan; Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Tosti","sequence":"additional","affiliation":[{"name":"Melanoma and Sarcoma Surgery; European Institute of Oncology; Milan; Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Grassi","sequence":"additional","affiliation":[{"name":"Melanoma and Sarcoma Surgery; European Institute of Oncology; Milan; Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Pari","sequence":"additional","affiliation":[{"name":"Melanoma and Sarcoma Surgery; European Institute of Oncology; Milan; Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Pennacchioli","sequence":"additional","affiliation":[{"name":"Melanoma and Sarcoma Surgery; European Institute of Oncology; Milan; Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2012,10,9]]},"reference":[{"issue":"5","key":"10.1111\/j.1529-8019.2012.01486.x-BIB0001|dth1486-cit-0001","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1245\/s10434-007-9717-9","article-title":"Prognosis and determinants of outcome following loco-regional or distant recurrence in patients with cutaneous melanoma","volume":"15","author":"Francken","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"36","key":"10.1111\/j.1529-8019.2012.01486.x-BIB0002|dth1486-cit-0002","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0003|dth1486-cit-0003","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/archsurg.139.11.1237","article-title":"Isolated limb perfusion for unresectable melanoma of the extremities","volume":"139","author":"Noorda","year":"2004","journal-title":"Arch Surg"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0004|dth1486-cit-0004","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/107327480801500305","article-title":"Therapy for unresectable recurrent and in-transit extremity melanoma","volume":"15","author":"Gimbel","year":"2008","journal-title":"Cancer Control"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0005|dth1486-cit-0005","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejcsup.2006.08.005","article-title":"Bases and rationale of the electrochemotherapy","volume":"4","author":"Mir","year":"2006","journal-title":"Eur J Cancer Suppl."},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0006|dth1486-cit-0006","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/02656730701832334","article-title":"Electrochemotherapy: an emerging cancer treatment","volume":"24","author":"Sadadcharam","year":"2008","journal-title":"Int J Hyperthermia"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0007|dth1486-cit-0007","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1038\/bjc.1998.388","article-title":"Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy","volume":"77","author":"Mir","year":"1998","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1111\/j.1529-8019.2012.01486.x-BIB0008|dth1486-cit-0008","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1529-8019.2010.01370.x","article-title":"Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach","volume":"23","author":"Testori","year":"2010","journal-title":"Dermatol Ther"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0009|dth1486-cit-0009","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1586\/14737140.6.5.671","article-title":"Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors","volume":"6","author":"Byrne","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0010|dth1486-cit-0010","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/archderm.1996.03890350095015","article-title":"Bleomycin-mediated electrochemotherapy of metastatic melanoma","volume":"132","author":"Glass","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0011|dth1486-cit-0011","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/(SICI)1097-0142(19980701)83:1<148::AID-CNCR20>3.0.CO;2-W","article-title":"Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin","volume":"83","author":"Heller","year":"1998","journal-title":"Cancer"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0012|dth1486-cit-0012","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1245\/s10434-008-9976-0","article-title":"Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases","volume":"15","author":"Quaglino","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1111\/j.1529-8019.2012.01486.x-BIB0013|dth1486-cit-0013","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00008390-199412000-00004","article-title":"Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma","volume":"4","author":"Clark","year":"1994","journal-title":"Melanoma Res"},{"issue":"11","key":"10.1111\/j.1529-8019.2012.01486.x-BIB0014|dth1486-cit-0014","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/archsurg.140.11.1115","article-title":"Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response","volume":"140","author":"Aloia","year":"2005","journal-title":"Arch Surg"},{"issue":"7","key":"10.1111\/j.1529-8019.2012.01486.x-BIB0015|dth1486-cit-0015","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1470-2045(03)01141-0","article-title":"Current uses of isolated limb perfusion in the clinic and a model system for new strategies","volume":"4","author":"Eggermont","year":"2003","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1111\/j.1529-8019.2012.01486.x-BIB0016|dth1486-cit-0016","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02071525","article-title":"Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs","volume":"16","author":"Thompson","year":"1992","journal-title":"World J Surg"},{"issue":"1","key":"10.1111\/j.1529-8019.2012.01486.x-BIB0017|dth1486-cit-0017","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JCO.2009.23.7511","article-title":"Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters","volume":"28","author":"Alexander","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0018|dth1486-cit-0018","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archsurg.1997.01430320105017","article-title":"Frequency and duration of remission after isolated limb perfusion for melanoma","volume":"132","author":"Thompson","year":"1997","journal-title":"Arch Surg"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0019|dth1486-cit-0019","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/jso.21949","article-title":"Results of isolated lower limb perfusion for loco-regional advanced\/recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases","volume":"104","author":"Pace","year":"2011","journal-title":"J Surg Oncol"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0020|dth1486-cit-0020","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1245\/s10434-011-2030-7","article-title":"20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters","volume":"19","author":"Deroose","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1111\/j.1529-8019.2012.01486.x-BIB0021|dth1486-cit-0021","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1245\/ASO.2004.03.019","article-title":"Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases","volume":"11","author":"Rossi","year":"2004","journal-title":"Ann Surg Oncol"},{"issue":"25","key":"10.1111\/j.1529-8019.2012.01486.x-BIB0022|dth1486-cit-0022","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1200\/JCO.2005.05.5152","article-title":"Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020","volume":"24","author":"Cornett","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0023|dth1486-cit-0023","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1245\/s10434-010-1104-2","article-title":"Long-term results of melphalan-based isolated limb perfusion with or without low-dose TNF for in-transit melanoma metastases","volume":"17","author":"Rossi","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1111\/j.1529-8019.2012.01486.x-BIB0024|dth1486-cit-0024","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1200\/JCO.2006.09.8459","article-title":"Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs","volume":"25","author":"Lejeune","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0025|dth1486-cit-0025","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/01.sla.0000146147.89667.ed","article-title":"One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases","volume":"240","author":"Gr\u00fcnhagen","year":"2004","journal-title":"Ann Surg"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0026|dth1486-cit-0026","first-page":"189","article-title":"Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion","volume":"44","author":"Mian","year":"2001","journal-title":"Can J Surg"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0027|dth1486-cit-0027","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1245\/s10434-008-9988-9","article-title":"Isolated limb infusion for in-transit malignant melanoma of the extremity: a well tolerated but less effective alternative to hyperthermic isolated limb perfusion","volume":"15","author":"Beasley","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0028|dth1486-cit-0028","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1245\/s10434-009-0717-9","article-title":"Isolated limb infusion for malignant melanoma: predictors of response and outcome","volume":"16","author":"Barbour","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0029|dth1486-cit-0029","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1245\/aso.2002.9.2.127","article-title":"Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma","volume":"9","author":"Lindn\u00e9r","year":"2002","journal-title":"Ann Surg Oncol"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0030|dth1486-cit-0030","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1245\/s10434-008-9954-6","article-title":"Outcomes of isolated limb infusion for melanoma. A 14-year experience","volume":"15","author":"Kroon","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0031|dth1486-cit-0031","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1097\/SLA.0b013e3181a77ce5","article-title":"Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced loco-regional melanoma","volume":"246","author":"Kroon","year":"2009","journal-title":"Ann Surg"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0032|dth1486-cit-0032","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1245\/s10434-009-0323-x","article-title":"Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin-D in melanoma patients","volume":"16","author":"Kroon","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0033|dth1486-cit-0033","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1002\/cncr.24220","article-title":"Efficacy of repeat isolated limb infusion with melphalan and actinomycin-D for recurrent melanoma","volume":"115","author":"Kroon","year":"2009","journal-title":"Cancer"},{"issue":"4","key":"10.1111\/j.1529-8019.2012.01486.x-BIB0034|dth1486-cit-0034","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ejso.2004.01.015","article-title":"Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma","volume":"30","author":"Lindner","year":"2004","journal-title":"Eur J Surg Oncol"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0035|dth1486-cit-0035","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jamcollsurg.2008.12.019","article-title":"A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US","volume":"208","author":"Beasley","year":"2009","journal-title":"J Am Coll Surg"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0036|dth1486-cit-0036","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1002\/cncr.24509","article-title":"A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma","volume":"115","author":"Beasley","year":"2009","journal-title":"Cancer"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0037|dth1486-cit-0037","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF01556582","article-title":"The role of immunotherapy in the management of patients with malignant melanoma","volume":"3","author":"Goodnight","year":"1979","journal-title":"World J Surg"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0038|dth1486-cit-0038","first-page":"158","article-title":"Immunological factors which influence response to immunotherapy in malignant melanoma","volume":"68","author":"Morton","year":"1970","journal-title":"Surgery"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0039|dth1486-cit-0039","first-page":"17","article-title":"Treatment for melanoma of the lower extremity with intralesional injection of bacilli Calmette Guerin and hyperthermic perfusion","volume":"149","author":"Storm","year":"1979","journal-title":"Surg Gynecol Obstet"},{"issue":"6","key":"10.1111\/j.1529-8019.2012.01486.x-BIB0040|dth1486-cit-0040","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1002\/1097-0142(197806)41:6<2456::AID-CNCR2820410654>3.0.CO;2-B","article-title":"Intralesional treatment of recurrent metastatic cutaneous melanoma: a randomized prospective study of intralesional bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene","volume":"41","author":"Cohen","year":"1978","journal-title":"Cancer"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0041|dth1486-cit-0041","unstructured":"Faries M Foshag L Essner R Morton D Intralesional BCG Immunotherapy in Metastatic Melanoma 2005"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0042|dth1486-cit-0042","first-page":"276","article-title":"Long-term results of intralesional BCG for locally advanced recurrent melanoma","volume":"9","author":"Bauer","year":"1990","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0043|dth1486-cit-0043","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1056\/NEJM197310182891603","article-title":"Complications of BCG immunotherapy in patients with cancer","volume":"289","author":"Sparks","year":"1973","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1111\/j.1529-8019.2012.01486.x-BIB0044|dth1486-cit-0044","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/sj.bjc.6601320","article-title":"Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases","volume":"89","author":"Radny","year":"2003","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1111\/j.1529-8019.2012.01486.x-BIB0045|dth1486-cit-0045","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00262-008-0455-z","article-title":"Local therapy of cancer with free IL-2","volume":"57","author":"Den Otter","year":"2008","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1111\/j.1529-8019.2012.01486.x-BIB0046|dth1486-cit-0046","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/1097-0142(19880315)61:6<1071::AID-CNCR2820610603>3.0.CO;2-T","article-title":"Intralesional interferon-alpha therapy in advanced malignant melanoma","volume":"61","author":"Von Wussow","year":"1988","journal-title":"Cancer"},{"issue":"3","key":"10.1111\/j.1529-8019.2012.01486.x-BIB0047|dth1486-cit-0047","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1468-3083.2001.00254.x","article-title":"Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients","volume":"15","author":"Ridolfi","year":"2001","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1111\/j.1529-8019.2012.01486.x-BIB0048|dth1486-cit-0048","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00008390-199606000-00008","article-title":"Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF","volume":"6","author":"Si","year":"1996","journal-title":"Melanoma Res"},{"issue":"3","key":"10.1111\/j.1529-8019.2012.01486.x-BIB0049|dth1486-cit-0049","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1245\/s10434-009-0809-6","article-title":"Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma","volume":"17","author":"Kaufman","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1111\/j.1529-8019.2012.01486.x-BIB0050|dth1486-cit-0050","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-2133.2006.07664.x","article-title":"Phase I\/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma","volume":"156","author":"Green","year":"2007","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1111\/j.1529-8019.2012.01486.x-BIB0051|dth1486-cit-0051","first-page":"1","article-title":"Novel dermatologic uses of the immune response modifier imiquimod 5% cream","volume":"7","author":"Berman","year":"2002","journal-title":"Skin Therapy Lett"},{"issue":"12","key":"10.1111\/j.1529-8019.2012.01486.x-BIB0052|dth1486-cit-0052","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1097-0142(20001215)89:12<2646::AID-CNCR18>3.0.CO;2-A","article-title":"Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer","volume":"89","author":"Triozzi","year":"2000","journal-title":"Cancer"},{"issue":"14","key":"10.1111\/j.1529-8019.2012.01486.x-BIB0053|dth1486-cit-0053","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1158\/1078-0432.CCR-07-4711","article-title":"Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients","volume":"14","author":"Molenkamp","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1111\/j.1529-8019.2012.01486.x-BIB0054|dth1486-cit-0054","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/CMR.0b013e32831328c7","article-title":"Chemoablation of metastatic melanoma using intralesional Rose Bengal","volume":"18","author":"Thompson","year":"2008","journal-title":"Melanoma Res"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1529-8019.2012.01486.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1529-8019.2012.01486.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T17:59:16Z","timestamp":1671818356000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1529-8019.2012.01486.x"}},"subtitle":["Treatment of locally advanced disease in melanoma"],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,9]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1529-8019.2012.01486.x","relation":{},"ISSN":["1396-0296"],"issn-type":[{"value":"1396-0296","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}